Noel Mueller
Concepts (500)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 26 | 2025 | 697 | 8.800 |
Why?
| | Cesarean Section | 14 | 2025 | 184 | 5.100 |
Why?
| | Microbiota | 15 | 2024 | 762 | 4.920 |
Why?
| | Delivery, Obstetric | 10 | 2022 | 144 | 3.970 |
Why?
| | Fatty Acids, Volatile | 8 | 2025 | 56 | 3.410 |
Why?
| | Pre-Eclampsia | 7 | 2025 | 190 | 3.170 |
Why?
| | Adiposity | 11 | 2024 | 518 | 2.890 |
Why?
| | Pediatric Obesity | 13 | 2025 | 601 | 2.710 |
Why?
| | Trace Elements | 4 | 2021 | 51 | 2.690 |
Why?
| | Body Mass Index | 30 | 2025 | 2389 | 2.550 |
Why?
| | Menarche | 7 | 2023 | 60 | 2.490 |
Why?
| | Hypertension | 12 | 2025 | 1295 | 2.340 |
Why?
| | Blood Pressure | 17 | 2025 | 1786 | 2.230 |
Why?
| | Pregnancy | 42 | 2025 | 6763 | 2.200 |
Why?
| | Feces | 11 | 2024 | 484 | 2.090 |
Why?
| | Prenatal Exposure Delayed Effects | 10 | 2024 | 605 | 2.010 |
Why?
| | Metals, Heavy | 3 | 2021 | 31 | 2.010 |
Why?
| | Mothers | 13 | 2023 | 754 | 1.780 |
Why?
| | Vagina | 7 | 2024 | 187 | 1.730 |
Why?
| | Dietary Approaches To Stop Hypertension | 4 | 2025 | 13 | 1.660 |
Why?
| | Diabetes Mellitus, Type 2 | 14 | 2025 | 2531 | 1.570 |
Why?
| | Female | 107 | 2025 | 73304 | 1.540 |
Why?
| | Dietary Fiber | 3 | 2023 | 54 | 1.490 |
Why?
| | Metformin | 5 | 2022 | 331 | 1.480 |
Why?
| | Infant, Newborn | 24 | 2025 | 6079 | 1.430 |
Why?
| | Breast Feeding | 4 | 2025 | 440 | 1.400 |
Why?
| | Humans | 140 | 2025 | 137585 | 1.370 |
Why?
| | Fetal Blood | 4 | 2022 | 327 | 1.360 |
Why?
| | Milk, Human | 2 | 2024 | 158 | 1.350 |
Why?
| | Carbonated Beverages | 3 | 2015 | 16 | 1.300 |
Why?
| | Infant | 28 | 2025 | 9465 | 1.270 |
Why?
| | Dietary Carbohydrates | 3 | 2021 | 155 | 1.260 |
Why?
| | Premature Birth | 2 | 2023 | 333 | 1.200 |
Why?
| | Dietary Proteins | 2 | 2020 | 135 | 1.190 |
Why?
| | Obesity | 15 | 2022 | 2992 | 1.110 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 2111 | 1.110 |
Why?
| | Longevity | 2 | 2019 | 165 | 1.090 |
Why?
| | Prospective Studies | 23 | 2025 | 7604 | 1.090 |
Why?
| | Methylamines | 2 | 2024 | 34 | 1.020 |
Why?
| | Diet | 15 | 2024 | 1278 | 1.010 |
Why?
| | Metabolome | 3 | 2024 | 350 | 1.000 |
Why?
| | Male | 76 | 2025 | 67762 | 0.990 |
Why?
| | Child | 36 | 2025 | 21935 | 0.980 |
Why?
| | Non-Nutritive Sweeteners | 2 | 2015 | 5 | 0.980 |
Why?
| | Adult | 58 | 2024 | 37929 | 0.980 |
Why?
| | Health Impact Assessment | 2 | 2022 | 9 | 0.920 |
Why?
| | Diet, Sodium-Restricted | 3 | 2025 | 36 | 0.890 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2024 | 86 | 0.870 |
Why?
| | Selenium | 2 | 2021 | 43 | 0.870 |
Why?
| | Longitudinal Studies | 13 | 2024 | 2844 | 0.850 |
Why?
| | Anti-Bacterial Agents | 5 | 2020 | 1809 | 0.850 |
Why?
| | Insulin Resistance | 6 | 2022 | 1208 | 0.830 |
Why?
| | Bacteria | 5 | 2023 | 858 | 0.830 |
Why?
| | Sugars | 1 | 2023 | 41 | 0.830 |
Why?
| | Risk Factors | 34 | 2024 | 10388 | 0.820 |
Why?
| | Infant Nutritional Physiological Phenomena | 3 | 2020 | 146 | 0.820 |
Why?
| | Manganese | 2 | 2020 | 62 | 0.820 |
Why?
| | Leg | 2 | 2015 | 236 | 0.810 |
Why?
| | Air Pollution | 3 | 2022 | 316 | 0.810 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 60 | 0.780 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 5472 | 0.760 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2024 | 549 | 0.760 |
Why?
| | Blood Pressure Determination | 3 | 2019 | 157 | 0.740 |
Why?
| | Diet, Mediterranean | 1 | 2022 | 30 | 0.740 |
Why?
| | Body Composition | 3 | 2025 | 684 | 0.740 |
Why?
| | Overweight | 10 | 2021 | 558 | 0.720 |
Why?
| | Chorioamnionitis | 1 | 2021 | 42 | 0.720 |
Why?
| | HTLV-I Infections | 10 | 2000 | 24 | 0.710 |
Why?
| | Child, Preschool | 17 | 2025 | 11074 | 0.710 |
Why?
| | Birth Weight | 7 | 2024 | 516 | 0.710 |
Why?
| | Hypotension | 1 | 2022 | 122 | 0.710 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 59 | 0.680 |
Why?
| | Fats, Unsaturated | 1 | 2020 | 1 | 0.670 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2020 | 23 | 0.650 |
Why?
| | Weight Gain | 3 | 2018 | 519 | 0.640 |
Why?
| | Flatulence | 1 | 2019 | 2 | 0.640 |
Why?
| | Dyspepsia | 1 | 2019 | 10 | 0.630 |
Why?
| | Body Fluids | 1 | 2019 | 66 | 0.630 |
Why?
| | Androgens | 1 | 2020 | 187 | 0.610 |
Why?
| | Pressure | 1 | 2020 | 225 | 0.600 |
Why?
| | Cohort Studies | 14 | 2023 | 5742 | 0.590 |
Why?
| | Abdominal Pain | 1 | 2020 | 145 | 0.590 |
Why?
| | Vitamin D Deficiency | 1 | 2020 | 186 | 0.580 |
Why?
| | Disinfectants | 1 | 2018 | 39 | 0.580 |
Why?
| | Boston | 6 | 2021 | 91 | 0.570 |
Why?
| | Bayes Theorem | 5 | 2024 | 405 | 0.570 |
Why?
| | Vitamin D | 2 | 2023 | 397 | 0.570 |
Why?
| | Middle Aged | 40 | 2025 | 33479 | 0.570 |
Why?
| | Waist Circumference | 4 | 2016 | 143 | 0.570 |
Why?
| | Estrogens | 1 | 2020 | 367 | 0.550 |
Why?
| | Skinfold Thickness | 2 | 2018 | 46 | 0.540 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 279 | 0.540 |
Why?
| | Biomarkers | 5 | 2024 | 4149 | 0.530 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 812 | 0.520 |
Why?
| | Age Factors | 6 | 2020 | 3295 | 0.510 |
Why?
| | Weight Loss | 5 | 2022 | 787 | 0.510 |
Why?
| | Puberty | 2 | 2014 | 146 | 0.500 |
Why?
| | Absorptiometry, Photon | 3 | 2025 | 259 | 0.500 |
Why?
| | Young Adult | 18 | 2021 | 13209 | 0.500 |
Why?
| | Gastrointestinal Tract | 2 | 2015 | 195 | 0.490 |
Why?
| | Rural Population | 3 | 2018 | 563 | 0.480 |
Why?
| | Singapore | 5 | 2013 | 22 | 0.480 |
Why?
| | Adolescent | 24 | 2022 | 21513 | 0.470 |
Why?
| | Infant Welfare | 1 | 2014 | 9 | 0.460 |
Why?
| | Asthma | 3 | 2022 | 2295 | 0.450 |
Why?
| | Brazil | 7 | 2016 | 167 | 0.450 |
Why?
| | Abdominal Fat | 1 | 2014 | 41 | 0.450 |
Why?
| | Leptin | 1 | 2016 | 236 | 0.440 |
Why?
| | Health Status | 3 | 2023 | 792 | 0.440 |
Why?
| | Adiponectin | 1 | 2016 | 244 | 0.430 |
Why?
| | Intra-Abdominal Fat | 2 | 2024 | 91 | 0.420 |
Why?
| | Metabolic Syndrome | 4 | 2021 | 354 | 0.420 |
Why?
| | Baltimore | 2 | 2024 | 60 | 0.420 |
Why?
| | Chronic Disease | 1 | 2019 | 1793 | 0.410 |
Why?
| | Diabetes, Gestational | 2 | 2018 | 318 | 0.410 |
Why?
| | Vitamins | 3 | 2024 | 185 | 0.410 |
Why?
| | Glucose | 2 | 2015 | 1020 | 0.410 |
Why?
| | Inflammation | 1 | 2024 | 2837 | 0.410 |
Why?
| | Feeding Behavior | 2 | 2017 | 654 | 0.410 |
Why?
| | Dyslipidemias | 1 | 2015 | 176 | 0.400 |
Why?
| | Multicenter Studies as Topic | 2 | 2024 | 310 | 0.400 |
Why?
| | Linear Models | 6 | 2018 | 849 | 0.400 |
Why?
| | Wrist | 1 | 2013 | 54 | 0.400 |
Why?
| | Parity | 1 | 2013 | 126 | 0.400 |
Why?
| | Anthropometry | 1 | 2013 | 213 | 0.390 |
Why?
| | Fetal Development | 1 | 2016 | 296 | 0.390 |
Why?
| | Social Class | 1 | 2015 | 282 | 0.390 |
Why?
| | Aged | 23 | 2025 | 23961 | 0.390 |
Why?
| | Time Factors | 9 | 2024 | 6828 | 0.380 |
Why?
| | Herpesvirus 4, Human | 5 | 1998 | 166 | 0.380 |
Why?
| | Fatty Liver | 1 | 2014 | 243 | 0.380 |
Why?
| | Soy Foods | 1 | 2011 | 5 | 0.370 |
Why?
| | Soybean Proteins | 1 | 2011 | 14 | 0.370 |
Why?
| | Isoflavones | 1 | 2011 | 26 | 0.370 |
Why?
| | Micronutrients | 2 | 2023 | 92 | 0.370 |
Why?
| | Liver | 1 | 2020 | 1943 | 0.370 |
Why?
| | Environmental Pollutants | 2 | 2024 | 159 | 0.360 |
Why?
| | Gestational Age | 3 | 2021 | 910 | 0.360 |
Why?
| | Butyrates | 2 | 2022 | 61 | 0.350 |
Why?
| | Social Determinants of Health | 1 | 2015 | 267 | 0.350 |
Why?
| | Obesity, Abdominal | 3 | 2016 | 48 | 0.340 |
Why?
| | Renal Dialysis | 2 | 2024 | 435 | 0.330 |
Why?
| | Bifidobacterium | 2 | 2021 | 20 | 0.330 |
Why?
| | Risk Assessment | 6 | 2024 | 3457 | 0.330 |
Why?
| | Probiotics | 2 | 2021 | 54 | 0.320 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 623 | 0.320 |
Why?
| | Maternal Exposure | 2 | 2024 | 190 | 0.320 |
Why?
| | Child Health | 2 | 2023 | 154 | 0.320 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 136 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1477 | 0.310 |
Why?
| | Protective Factors | 3 | 2019 | 93 | 0.300 |
Why?
| | Follow-Up Studies | 8 | 2018 | 5131 | 0.300 |
Why?
| | Papillomavirus Vaccines | 1 | 2012 | 238 | 0.300 |
Why?
| | Socioeconomic Factors | 7 | 2021 | 1289 | 0.290 |
Why?
| | Denmark | 2 | 2025 | 46 | 0.290 |
Why?
| | Beverages | 2 | 2023 | 69 | 0.290 |
Why?
| | Case-Control Studies | 7 | 2023 | 3556 | 0.280 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 617 | 0.280 |
Why?
| | Papillomavirus Infections | 1 | 2012 | 325 | 0.280 |
Why?
| | Women, Working | 2 | 2017 | 12 | 0.280 |
Why?
| | Prevalence | 10 | 2024 | 2734 | 0.280 |
Why?
| | Logistic Models | 7 | 2023 | 2074 | 0.270 |
Why?
| | Quality of Life | 1 | 2019 | 2892 | 0.270 |
Why?
| | Autism Spectrum Disorder | 2 | 2024 | 395 | 0.260 |
Why?
| | Hodgkin Disease | 3 | 1998 | 138 | 0.260 |
Why?
| | Body Size | 2 | 2018 | 108 | 0.250 |
Why?
| | Sodium, Dietary | 3 | 2025 | 41 | 0.250 |
Why?
| | Incidence | 7 | 2022 | 2804 | 0.250 |
Why?
| | Interviews as Topic | 3 | 2015 | 786 | 0.240 |
Why?
| | Emergency Medical Services | 1 | 2012 | 552 | 0.240 |
Why?
| | Infant, Low Birth Weight | 2 | 2016 | 141 | 0.240 |
Why?
| | Quebec | 1 | 2025 | 11 | 0.240 |
Why?
| | City Planning | 2 | 2022 | 3 | 0.230 |
Why?
| | Blood Glucose | 5 | 2021 | 2186 | 0.230 |
Why?
| | Sleep | 2 | 2023 | 755 | 0.230 |
Why?
| | Pregnancy Complications | 3 | 2024 | 527 | 0.230 |
Why?
| | Pregnancy Trimester, First | 2 | 2024 | 140 | 0.220 |
Why?
| | Cities | 2 | 2022 | 133 | 0.220 |
Why?
| | Infectious Mononucleosis | 2 | 1998 | 10 | 0.220 |
Why?
| | Folic Acid | 3 | 2024 | 186 | 0.220 |
Why?
| | Ohio | 2 | 2015 | 152 | 0.220 |
Why?
| | Bacteroides fragilis | 1 | 2024 | 13 | 0.220 |
Why?
| | Diet, Vegetarian | 1 | 2024 | 8 | 0.220 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2024 | 23 | 0.220 |
Why?
| | Chemokine CCL2 | 1 | 2024 | 115 | 0.220 |
Why?
| | Biometry | 1 | 2024 | 70 | 0.220 |
Why?
| | Homeostasis | 3 | 2016 | 621 | 0.210 |
Why?
| | Antibodies, Viral | 6 | 1991 | 625 | 0.210 |
Why?
| | Oligosaccharides | 1 | 2024 | 60 | 0.210 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.210 |
Why?
| | Research Design | 2 | 2021 | 1139 | 0.210 |
Why?
| | Clostridiales | 1 | 2023 | 3 | 0.210 |
Why?
| | Vitamin A | 1 | 2023 | 58 | 0.210 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2828 | 0.210 |
Why?
| | Mucus | 1 | 2024 | 79 | 0.210 |
Why?
| | Metals | 1 | 2024 | 136 | 0.200 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1329 | 0.200 |
Why?
| | Maternal Age | 1 | 2023 | 129 | 0.200 |
Why?
| | Nutrition Assessment | 2 | 2015 | 92 | 0.200 |
Why?
| | Tryptophan | 1 | 2024 | 183 | 0.200 |
Why?
| | Aging | 2 | 2024 | 1864 | 0.200 |
Why?
| | Cannabidiol | 1 | 2024 | 119 | 0.200 |
Why?
| | Phthalic Acids | 1 | 2022 | 40 | 0.190 |
Why?
| | Dronabinol | 1 | 2024 | 226 | 0.190 |
Why?
| | District of Columbia | 3 | 2021 | 28 | 0.190 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 72 | 0.190 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 255 | 0.180 |
Why?
| | Obesity Management | 1 | 2021 | 8 | 0.180 |
Why?
| | Urban Health | 1 | 2022 | 92 | 0.180 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 938 | 0.180 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2021 | 39 | 0.180 |
Why?
| | Regression Analysis | 3 | 2012 | 1024 | 0.180 |
Why?
| | HTLV-I Antibodies | 5 | 1992 | 6 | 0.180 |
Why?
| | Sodium | 2 | 2021 | 217 | 0.180 |
Why?
| | Hepatitis C | 3 | 2000 | 271 | 0.180 |
Why?
| | Registries | 2 | 2024 | 2035 | 0.180 |
Why?
| | Permeability | 1 | 2022 | 161 | 0.180 |
Why?
| | Glycemic Index | 1 | 2021 | 27 | 0.180 |
Why?
| | Purines | 1 | 2022 | 176 | 0.180 |
Why?
| | Cardiovascular System | 1 | 2023 | 137 | 0.180 |
Why?
| | Clostridium perfringens | 1 | 2021 | 5 | 0.180 |
Why?
| | Clostridium | 1 | 2021 | 17 | 0.180 |
Why?
| | Oxides | 1 | 2021 | 46 | 0.180 |
Why?
| | Bacteroides | 1 | 2021 | 21 | 0.180 |
Why?
| | Sex Characteristics | 2 | 2016 | 762 | 0.180 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 117 | 0.180 |
Why?
| | Growth | 1 | 2021 | 60 | 0.170 |
Why?
| | Smoking | 4 | 2013 | 1627 | 0.170 |
Why?
| | Odds Ratio | 6 | 2023 | 1070 | 0.170 |
Why?
| | Minority Groups | 1 | 2022 | 266 | 0.170 |
Why?
| | Glomerular Filtration Rate | 1 | 2024 | 746 | 0.170 |
Why?
| | Uric Acid | 1 | 2021 | 163 | 0.170 |
Why?
| | Postpartum Period | 1 | 2023 | 340 | 0.170 |
Why?
| | Skin Absorption | 1 | 2019 | 12 | 0.160 |
Why?
| | Models, Statistical | 1 | 2024 | 669 | 0.160 |
Why?
| | Massachusetts | 1 | 2020 | 172 | 0.160 |
Why?
| | Dysbiosis | 1 | 2021 | 181 | 0.160 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 88 | 0.160 |
Why?
| | Vulnerable Populations | 1 | 2021 | 163 | 0.160 |
Why?
| | Interdisciplinary Research | 1 | 2020 | 27 | 0.160 |
Why?
| | Appetite | 1 | 2020 | 69 | 0.160 |
Why?
| | Digestive System | 1 | 2019 | 27 | 0.160 |
Why?
| | Sex Factors | 4 | 2019 | 2071 | 0.160 |
Why?
| | Cost of Illness | 1 | 2022 | 308 | 0.160 |
Why?
| | Mercury | 1 | 2019 | 41 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2024 | 1242 | 0.150 |
Why?
| | Cholesterol, HDL | 1 | 2020 | 203 | 0.150 |
Why?
| | Cadmium | 1 | 2019 | 69 | 0.150 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2021 | 319 | 0.150 |
Why?
| | Lead | 1 | 2019 | 64 | 0.150 |
Why?
| | Venezuela | 1 | 2018 | 8 | 0.150 |
Why?
| | Men's Health | 1 | 2018 | 7 | 0.150 |
Why?
| | Employment | 2 | 2017 | 178 | 0.150 |
Why?
| | United States | 8 | 2023 | 14841 | 0.150 |
Why?
| | United States Food and Drug Administration | 1 | 2019 | 208 | 0.150 |
Why?
| | Behavior Therapy | 1 | 2021 | 264 | 0.150 |
Why?
| | Age Distribution | 2 | 2018 | 392 | 0.150 |
Why?
| | DNA, Bacterial | 1 | 2020 | 337 | 0.150 |
Why?
| | Dizziness | 1 | 2019 | 82 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2024 | 570 | 0.150 |
Why?
| | Skin | 1 | 2023 | 752 | 0.140 |
Why?
| | Age of Onset | 2 | 2016 | 518 | 0.140 |
Why?
| | Nutritional Status | 2 | 2024 | 350 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 886 | 0.140 |
Why?
| | Cholesterol, LDL | 1 | 2020 | 365 | 0.140 |
Why?
| | Health Status Disparities | 1 | 2021 | 289 | 0.140 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2018 | 77 | 0.140 |
Why?
| | Nutrition Surveys | 2 | 2021 | 266 | 0.140 |
Why?
| | Surveys and Questionnaires | 4 | 2014 | 5778 | 0.140 |
Why?
| | Reference Values | 1 | 2019 | 816 | 0.140 |
Why?
| | Infant, Small for Gestational Age | 1 | 2018 | 92 | 0.140 |
Why?
| | Public Health | 2 | 2021 | 588 | 0.140 |
Why?
| | Leukocytes | 1 | 2018 | 311 | 0.130 |
Why?
| | Verrucomicrobia | 1 | 2016 | 5 | 0.130 |
Why?
| | Computational Biology | 1 | 2021 | 644 | 0.130 |
Why?
| | Japan | 6 | 2000 | 115 | 0.130 |
Why?
| | Colombia | 2 | 2016 | 41 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1050 | 0.130 |
Why?
| | Confidence Intervals | 2 | 2012 | 329 | 0.130 |
Why?
| | Developing Countries | 2 | 2017 | 307 | 0.130 |
Why?
| | Income | 1 | 2017 | 202 | 0.130 |
Why?
| | Disease Progression | 1 | 2024 | 2757 | 0.130 |
Why?
| | Death | 1 | 2017 | 119 | 0.130 |
Why?
| | Phylogeny | 1 | 2020 | 904 | 0.120 |
Why?
| | Liver Neoplasms | 2 | 2000 | 786 | 0.120 |
Why?
| | Aspartame | 1 | 2015 | 3 | 0.120 |
Why?
| | Preconception Care | 1 | 2016 | 43 | 0.120 |
Why?
| | Particulate Matter | 1 | 2018 | 315 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1639 | 0.120 |
Why?
| | Intestines | 1 | 2018 | 357 | 0.120 |
Why?
| | Coffee | 1 | 2015 | 17 | 0.120 |
Why?
| | Epidemiologic Methods | 2 | 2013 | 97 | 0.120 |
Why?
| | Caffeine | 1 | 2015 | 68 | 0.110 |
Why?
| | Nutrition Policy | 1 | 2015 | 61 | 0.110 |
Why?
| | China | 1 | 2015 | 217 | 0.110 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 179 | 0.110 |
Why?
| | Animals | 7 | 2024 | 36940 | 0.110 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2015 | 108 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2024 | 10811 | 0.110 |
Why?
| | Dietary Supplements | 3 | 2024 | 561 | 0.110 |
Why?
| | Body Weight | 1 | 2019 | 985 | 0.110 |
Why?
| | Organ Size | 1 | 2015 | 477 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1266 | 0.110 |
Why?
| | California | 1 | 2015 | 431 | 0.110 |
Why?
| | Immunoglobulin M | 3 | 1991 | 289 | 0.100 |
Why?
| | Physical Examination | 1 | 2015 | 241 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4030 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1509 | 0.100 |
Why?
| | Analysis of Variance | 2 | 2015 | 1316 | 0.100 |
Why?
| | Glucose Metabolism Disorders | 1 | 2012 | 11 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2019 | 1317 | 0.100 |
Why?
| | Diabetic Angiopathies | 1 | 2014 | 259 | 0.100 |
Why?
| | Central America | 1 | 2012 | 24 | 0.090 |
Why?
| | South America | 1 | 2012 | 60 | 0.090 |
Why?
| | Capsid Proteins | 2 | 1991 | 94 | 0.090 |
Why?
| | Area Under Curve | 1 | 2012 | 314 | 0.090 |
Why?
| | Abdomen | 1 | 2012 | 125 | 0.090 |
Why?
| | Brain | 1 | 2023 | 2668 | 0.090 |
Why?
| | Demography | 3 | 2017 | 291 | 0.090 |
Why?
| | Antigens, Viral | 3 | 1999 | 178 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1991 | 87 | 0.090 |
Why?
| | ROC Curve | 1 | 2012 | 554 | 0.090 |
Why?
| | Immunoglobulin G | 3 | 1991 | 893 | 0.080 |
Why?
| | Cytokines | 1 | 2018 | 2085 | 0.080 |
Why?
| | Carrier State | 3 | 1998 | 67 | 0.080 |
Why?
| | Occupations | 3 | 2017 | 49 | 0.080 |
Why?
| | Dietary Sucrose | 1 | 2010 | 49 | 0.080 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2012 | 257 | 0.070 |
Why?
| | Diabetes Mellitus | 2 | 2016 | 1040 | 0.070 |
Why?
| | Health Promotion | 1 | 2015 | 741 | 0.070 |
Why?
| | Mice | 2 | 2024 | 17787 | 0.070 |
Why?
| | Epidemiology | 1 | 2008 | 33 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.070 |
Why?
| | India | 2 | 2021 | 195 | 0.070 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1291 | 0.070 |
Why?
| | Cytomegalovirus | 1 | 1988 | 157 | 0.070 |
Why?
| | Patient Selection | 1 | 2011 | 696 | 0.070 |
Why?
| | Smoking Cessation | 1 | 2011 | 442 | 0.070 |
Why?
| | Testicular Neoplasms | 1 | 1988 | 110 | 0.060 |
Why?
| | Human T-lymphotropic virus 1 | 2 | 1999 | 28 | 0.060 |
Why?
| | Nucleoside-Triphosphatase | 1 | 2006 | 6 | 0.060 |
Why?
| | Flavivirus | 1 | 2006 | 19 | 0.060 |
Why?
| | RNA Helicases | 1 | 2006 | 30 | 0.060 |
Why?
| | Waist-Hip Ratio | 2 | 2016 | 39 | 0.060 |
Why?
| | Viral Nonstructural Proteins | 1 | 2006 | 65 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1724 | 0.060 |
Why?
| | Lipids | 2 | 2022 | 672 | 0.060 |
Why?
| | Binomial Distribution | 1 | 2024 | 7 | 0.060 |
Why?
| | Spatial Analysis | 1 | 2024 | 20 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2691 | 0.060 |
Why?
| | Germany | 1 | 2024 | 121 | 0.060 |
Why?
| | Georgia | 1 | 2024 | 86 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2012 | 986 | 0.050 |
Why?
| | Insulin | 3 | 2021 | 2409 | 0.050 |
Why?
| | Appointments and Schedules | 1 | 2024 | 89 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2018 | 15657 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 564 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 157 | 0.050 |
Why?
| | Hospitalization | 2 | 2024 | 2199 | 0.050 |
Why?
| | Heartburn | 1 | 2021 | 12 | 0.050 |
Why?
| | Maryland | 1 | 2021 | 60 | 0.050 |
Why?
| | Nutritional Requirements | 1 | 2021 | 78 | 0.040 |
Why?
| | American Heart Association | 1 | 2023 | 306 | 0.040 |
Why?
| | Hunger | 1 | 2021 | 45 | 0.040 |
Why?
| | Gout | 1 | 2021 | 37 | 0.040 |
Why?
| | Iron | 1 | 2023 | 313 | 0.040 |
Why?
| | Africa, Eastern | 1 | 2020 | 12 | 0.040 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 2 | 1991 | 14 | 0.040 |
Why?
| | Transportation | 1 | 2020 | 53 | 0.040 |
Why?
| | Causality | 1 | 2020 | 126 | 0.040 |
Why?
| | Capital Financing | 1 | 2020 | 8 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 475 | 0.040 |
Why?
| | Tuberculin | 1 | 1999 | 8 | 0.040 |
Why?
| | Hepacivirus | 2 | 1998 | 261 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 207 | 0.040 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 77 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1993 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2019 | 116 | 0.040 |
Why?
| | Meconium | 1 | 2018 | 7 | 0.040 |
Why?
| | Oncogene Proteins, Viral | 1 | 1998 | 22 | 0.040 |
Why?
| | Viral Matrix Proteins | 1 | 1998 | 30 | 0.040 |
Why?
| | Th1 Cells | 1 | 1999 | 143 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 149 | 0.040 |
Why?
| | Aged, 80 and over | 5 | 1997 | 7635 | 0.040 |
Why?
| | Diet, Western | 1 | 2019 | 81 | 0.040 |
Why?
| | Virus Latency | 1 | 1998 | 80 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2022 | 579 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 114 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2018 | 108 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 410 | 0.030 |
Why?
| | Sex Distribution | 2 | 2014 | 375 | 0.030 |
Why?
| | Calcium | 1 | 2023 | 1199 | 0.030 |
Why?
| | Immunologic Memory | 1 | 1999 | 353 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 524 | 0.030 |
Why?
| | Cancer Survivors | 1 | 2021 | 285 | 0.030 |
Why?
| | Sarcoma, Kaposi | 1 | 1997 | 81 | 0.030 |
Why?
| | Mucins | 1 | 2016 | 73 | 0.030 |
Why?
| | Deltaretrovirus Antibodies | 1 | 1996 | 1 | 0.030 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2016 | 54 | 0.030 |
Why?
| | Viral Proteins | 1 | 1998 | 342 | 0.030 |
Why?
| | Health Care Costs | 1 | 2019 | 398 | 0.030 |
Why?
| | Health Behavior | 1 | 2021 | 762 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 416 | 0.030 |
Why?
| | Health Surveys | 1 | 2017 | 514 | 0.030 |
Why?
| | Disease Transmission, Infectious | 1 | 1996 | 62 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2018 | 370 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1357 | 0.030 |
Why?
| | Dominican Republic | 1 | 2015 | 24 | 0.030 |
Why?
| | Educational Status | 1 | 2017 | 470 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2019 | 546 | 0.030 |
Why?
| | RNA, Viral | 1 | 1998 | 656 | 0.030 |
Why?
| | New York | 1 | 2015 | 126 | 0.030 |
Why?
| | Gene Products, tax | 2 | 1991 | 13 | 0.030 |
Why?
| | Body Fat Distribution | 1 | 2014 | 49 | 0.030 |
Why?
| | Hyperlipidemias | 1 | 2015 | 120 | 0.030 |
Why?
| | Hepatitis B | 1 | 1995 | 70 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2015 | 366 | 0.030 |
Why?
| | Poverty | 1 | 2017 | 521 | 0.030 |
Why?
| | Communication | 1 | 2020 | 879 | 0.030 |
Why?
| | HTLV-I Antigens | 2 | 1991 | 2 | 0.030 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 2 | 1991 | 10 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4565 | 0.020 |
Why?
| | HIV Seroprevalence | 1 | 1992 | 4 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1946 | 0.020 |
Why?
| | Serologic Tests | 1 | 1992 | 54 | 0.020 |
Why?
| | Forestry | 1 | 1992 | 4 | 0.020 |
Why?
| | Fisheries | 1 | 1992 | 3 | 0.020 |
Why?
| | Leukemia, T-Cell | 1 | 1991 | 4 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1459 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1992 | 40 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1995 | 362 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 347 | 0.020 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 1991 | 21 | 0.020 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1991 | 3 | 0.020 |
Why?
| | Capsid | 1 | 1991 | 93 | 0.020 |
Why?
| | Agriculture | 1 | 1992 | 103 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3284 | 0.020 |
Why?
| | Sexually Transmitted Diseases | 1 | 1991 | 161 | 0.020 |
Why?
| | Dysgerminoma | 1 | 1988 | 6 | 0.020 |
Why?
| | Sexual Behavior | 1 | 1992 | 485 | 0.020 |
Why?
| | Immunoglobulin A | 1 | 1989 | 211 | 0.020 |
Why?
| | Science | 1 | 2008 | 53 | 0.020 |
Why?
| | United Kingdom | 1 | 2008 | 318 | 0.020 |
Why?
| | Teratoma | 1 | 1988 | 114 | 0.020 |
Why?
| | History, 20th Century | 1 | 2008 | 325 | 0.020 |
Why?
| | Neoplasms | 1 | 2021 | 2671 | 0.020 |
Why?
| | Risk | 1 | 1989 | 912 | 0.020 |
Why?
| | HIV-1 | 1 | 1992 | 864 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3196 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 2900 | 0.020 |
Why?
| | Health Personnel | 1 | 1992 | 710 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 385 | 0.010 |
Why?
| | Virus Replication | 1 | 1987 | 483 | 0.010 |
Why?
| | Recombinant Proteins | 2 | 1999 | 1353 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2139 | 0.010 |
Why?
| | Transcription Factors | 1 | 1989 | 1719 | 0.010 |
Why?
| | Tritium | 1 | 1999 | 76 | 0.010 |
Why?
| | Thymidine | 1 | 1999 | 60 | 0.010 |
Why?
| | Mycobacterium bovis | 1 | 1999 | 16 | 0.010 |
Why?
| | BCG Vaccine | 1 | 1999 | 24 | 0.010 |
Why?
| | Interleukin-12 | 1 | 1999 | 121 | 0.010 |
Why?
| | Erythema | 1 | 1998 | 29 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 1999 | 127 | 0.010 |
Why?
| | Blotting, Western | 2 | 1991 | 1226 | 0.010 |
Why?
| | Interleukin-2 | 1 | 1999 | 455 | 0.010 |
Why?
| | Cell Division | 1 | 1999 | 794 | 0.010 |
Why?
| | Greece | 1 | 1997 | 8 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1999 | 789 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1997 | 230 | 0.010 |
Why?
| | Hepatitis Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1995 | 24 | 0.010 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 1995 | 16 | 0.010 |
Why?
| | Hepatitis B virus | 1 | 1995 | 40 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 1995 | 165 | 0.010 |
Why?
| | Eye Diseases | 1 | 1995 | 87 | 0.010 |
Why?
| | Life Style | 1 | 1995 | 490 | 0.010 |
Why?
| | Homosexuality | 1 | 1992 | 17 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1995 | 325 | 0.010 |
Why?
| | Retroviruses, Simian | 1 | 1991 | 1 | 0.010 |
Why?
| | Genes, pX | 1 | 1991 | 2 | 0.010 |
Why?
| | Bisexuality | 1 | 1992 | 31 | 0.010 |
Why?
| | Papio | 1 | 1991 | 94 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1999 | 4193 | 0.010 |
Why?
| | Mexico | 1 | 1992 | 225 | 0.010 |
Why?
| | Agglutination Tests | 1 | 1991 | 4 | 0.010 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 1990 | 6 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1991 | 173 | 0.010 |
Why?
| | DNA, Viral | 1 | 1991 | 364 | 0.000 |
Why?
| | Autoradiography | 1 | 1989 | 78 | 0.000 |
Why?
| | Precipitin Tests | 1 | 1989 | 100 | 0.000 |
Why?
| | Antibody Formation | 1 | 1991 | 298 | 0.000 |
Why?
| | Lymphocytes | 1 | 1991 | 397 | 0.000 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 345 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1991 | 1062 | 0.000 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 852 | 0.000 |
Why?
| | Base Sequence | 1 | 1991 | 2181 | 0.000 |
Why?
| | Alcohol Drinking | 1 | 1995 | 828 | 0.000 |
Why?
| | Family | 1 | 1991 | 671 | 0.000 |
Why?
| | Trans-Activators | 1 | 1989 | 398 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2654 | 0.000 |
Why?
|
|
Mueller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|